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1. Introduction
  Lung cancer is the leading cause of cancer deaths in the 
world with over one million cases diagnosed every year. 
Multiple options for the treatment of lung cancer have been 
described, including surgery, chemotherapy, and radiation, 
however, therapeutic effect is typically transient and 
mostly absent with advanced disease[1,2]. Therefore, intense 
efforts are being mounted to find effective new agents and 
treatments against lung cancer.
  Casticin is one of the main components from Fructus 
viticis (Manjingzi in Chinese name), a traditional Chinese 
medicine prepared from the fruit of Vitex trifolia L. (family 
Verbenaceae) that is also used as a folk medicine to be 
an anti-inflammatory agent and treat certain cancers in 
Objective: To assess if casticin induces caspase-mediated apoptosis via activation of 
mitochondrial pathway and upregulation of DR5 in human lung cancer cells. Methods: Human 
non-small-cell lung carcinoma cell lines H460, A549 and H157 were cultured in vitro. The 
cytotoxic activities were determined using MTT assay. The apoptotic cells death was examined by 
flow cytometry using PI staining and DNA agarose gel electrophoresis. The activities of caspase-3, 
-8 and -9 were measured via ELISA. Cellular fractionation was determined by flow cytometry to 
assess release of cytochrome c and the mitochondrial transmembrane potential. Bcl-2/Bcl-XL/
XIAP/Bid/ DR5 and DR4 proteins were analyzed using western blot. Results: The concentrations 
required for a 50% decrease in cell growth (IC50) ranged from 1.8 to 3.2 毺M. Casticin induced 
rapid apoptosis and triggered a series of effects associated with apoptosis by way of mitochondrial 
pathway, including the depolarization of the mitochondrial membrane, release of cytochrome c 
from mitochondria, activation of procaspase-9 and -3, and increase of DNA fragments. Moreover, 
the pan caspase inhibitor zVAD-FMK and the caspase-3 inhibitor zDEVD-FMK suppressed 
casticin-induced apoptosis. In addition, casticin induced XIAP and Bcl-XL down-regulation, 
Bax upregulation and Bid clearage. In H157 cell line, casticin increased expression of DR5 
at protein levels but not affect the expression of DR4. The pretreatment with DR5/Fc chimera 
protein effectively attenuated casticin-induced apoptosis in H157 cells. No correlation was found 
between cell sensitivity to casticin and that to p53 status, suggesting that casticin induce a p53-
independent apoptosis. Conclusions: Our results demonstrate that casticin induces caspase-
mediated apoptosis via activation of mitochondrial pathway and upregulation of DR5 in human 
lung cancer cells.
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China[3]. Its chemical structure is shown in Figure 1. Casticin 
has been showed to inhibit lymphocyte proliferation in 
vitro[4] and has an anti-inflammatory effect in vivo[5]. In 
recent years, many studies have demonstrated its anti-
carcinogenic activity in various cancer cells, including lung 
cancer[6-8]. However, whether casticin induces apoptosis of 
carcinoma cells and its precise mechanisms are unclear.
  In this report, we examined the effects of casticin on 
apoptosis of human non-small cell lung carcinoma (NSCLC) 
cell lines. We show for the first time that casticin is a 
potent inducer of apoptosis in NSCLC cells and this effect is 
associated with activation of caspase through mitochondrial 
signaling and DR5 upregulation.
Figure 1. Chemcial constitution of casticin.
2. Materials and methods
2.1. Reagents
   Casticin was purchased from Chengdu Biopurify 
Phytochemicals Ltd. (Chengdu, China). Casticin has a 
molecular weight of 374.3 ku, appears as yellow crystals and 
has a purity of 98.0%. Casticin was prepared in dimethyl-
sulfoxide at a concentration of 10 mmol/L, and aliquots 
were stored at -80 曟. Stock solutions were diluted to the 
desired final concentrations with growth medium just before 
use. The following were purchased from Hunan Clonetimes 
Biotech Co., Ltd. (Changsha, China): RPMI-1640 medium 
(Invitrogen), fetal bovine serum (Invitrogen), Cell Apoptosis 
ELISA Detection Kit (Roche), Caspase 3 Activity Detection 
Kit (Millipore), Caspase 8 Colorimetric Activity Assay 
Kit 25 (Millipore), Caspase 9 Colorimetric Activity Assay 
Kit (Millipore), DR5/Fc chimera protein (R&D Systems), 
CBZ-Val-Ala-Asp-fluoromethyl ketone (zVAD-fmk: 
Livermore), CBZ-Asp-Glu-Val-Asp-fluoromethyl ketone 
(zDEVD-fmk: Livermore), Z-lle-Glu(Ome)-Thr-Asp(OMe)-
fluoromethyl ketone (zIETD-fmk: Livermore), and Z-Leu-
Glu(OMe)-His-Asp(OMe)-fluoromethyl ketone (zLEHD-fmk: 
Livermore), rhodamine 123 (Eugene), Mouse anti-human 
Bcl-2, Bax, XIAP, Bcl-XL, cytochrome c, DR5, DR4 and 毬
-actin antibodies (Santa Cruz Biotechnology), horseradish 
peroxidase-conjugated anti-mouse secondary antibody (Cell 
Signaling Technology).
2.2. Cell lines and cell culture
  Human non-small-cell lung carcinoma cell lines H460 and 
A549 which possess wild-type p53, and H157 which express 
mutant p53[9,10], were obtained from the American Type 
Culture Collection (Manassas, VA). Human embryo lung WI-
38 cells were purchased from cell bank, Chinese Academy 
of Sciences (Shanghai, China). These cells were cultured 
in RPMI 1640 supplemented with 100 units/mL penicillin, 
100 毺g/mL streptomycin, 1 mmol/L L-glutamine, and 10% 
heat-inactivated fetal bovine serum at 37 曟 in a humidified 
atmosphere consisting of 5% CO2 and 95% air.
 
2.3. MTT assay
  Cells were seeded in a 96-well plate at a density of 0.5暳10
4
cells/well for 24 h, followed by treatment with various 
concentrations of casticin or cisplatin for the indicated 
time. MTT colorimetric analysis was performed as described 
previously[11]. The IC50 value, at which 50% of the cell growth 
inhibition compared with DMSO control, was calculated by 
nonlinear regression analysis using GraphPad Prism software 
(San Diego, CA).
2.4. Flow cytometry using PI staining
  Cells were seeded at a density of 4暳10
6 cells/well in 250 mL
culture flasks for 24 h and then treated with the medium 
containing various concentrations of casticin and cisplatin 
for the indicated time. Propidium iodide staining for DNA 
content analysis was performed as described previously[10].
 
2.5. DNA fragmentation assay
  Cells were seeded at a density of 4暳10
6 cells/well in 
250 mL culture flasks for 24 h and treated with medium 
containing various concentrations of casticin or cisplatin for 
24 h. This assay was performed as described previously[12,13].
2.6. Histone/DNA ELISA for detecting apoptosis
  Cells were seeded in a 96-well plate at a density of 1暳10
4
cells/well for 24 h, added the tested agents and then 
cultured in RPMI-1640 medium containing 10% fetal bovine 
serum. After 24 h, the cytoplasm of the control and treatment 
group was transferred to the 96-well plate peridiumed by 
the streptavidin, incubated with the biotinylated histone 
antibody and peroxidase-tagged mouse anti-human 
DNA for 2 h at room temperature. The absorbance at 405 
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nm was measured with EXL-800 type Enzyme-Linked 
Immunosorbent apparatus.
2.7. Analysis of caspase-3, -8 and -9 activities
  To evaluate caspase activity, cell lysates were prepared 
after their respective treatment with the tested agents. 
Assays were performed in 96-well plates by incubating 20 毺g
cell lysates in 100 毺L reaction buffer (1% NP-40, 20 mM 
Tris-HCl (pH 7.5), 137 mM NaCl, 10% glycerol) containing 
a 5 毺M caspase-3 substrate Ac-DEVD-pNA or caspase-8 
substrate Ac-IETD- pNA or caspase-9 substrate Ac-LEHD- 
pNA. Lysates were incubated at 37 曟 for 2 h. Thereafter, 
the absorbance at 405 nm was measured with an enzyme-
labeling instrument (ELX-800 type). In the caspase inhibitors 
assay, cells were pretreated with a caspase inhibitor (20 毺M, 
zVAD-fmk or zDEVD-fmk or zIETD-fmk or zLEHD-fmk) for 
1 h prior to the addition of test agents.
2.8. Measurement of mitochondrial transmembrane potential
  The mitochondrial transmembrane potential was 
determined by flow cytometry after cell loading with 
rhodamine 123, as described by Troyano et al[14].
2.9. Cellular fractionation
  For assay of release of cytochrome c, cells were 
fractionated into cytosolic and mitochondrial fractions as 
described by Ling et al[15] In brief, cells were incubated in 
buffer containing 20 mM HEPES-KOH, pH 7.2, 10 mM KCl, 
1.5 mM MgCl2, 1 mM EDTA, 0.1 mM phenylmethylsulfonyl 
fluoride, 10 毺g/mL leupeptin, and 10 毺g/mL aprotinin 
at 4 曟 for 10 min, and then cells were homogenized with 
a Dounce homogenizer for 20 strokes. After addition of 
buffer containing 210 mM mannitol, 70 mM sucrose, 5 mM 
EGTA, and 5 mM Tris-HCl, pH 7.5, the homogenates were 
centrifuged at 1 000 g for 10 min at 4 曟. The supernatants 
were further centrifuged at 15 000 g for 30 min at 4 曟, and 
collected as the cytosolic fraction. The pellet was further 
dissolved with lysis buffer containing with 1% SDS as the 
mitochondrial fraction.
2.10. Western blot analysis
  Total cell extracts were obtained as previously described[12]. 
Cell lysate containing 50 毺g of protein was separated on 
a 7.5%-12.5% SDS-polyacrylamide gel for electrophoresis 
and then blotted onto polyvinylidene difluoride membranes 
(Millipore, Bedford, MA). Anti- Bcl-2, Bax, XIAP, Bcl-XL, 
cytochrome c, DR5, DR4 and 毬-actin (1:1 000 dilutions for 
each) were used as primary antibodies. Signals were detected 
using an ECL kit (Amersham Pharmacia Biotech, Piscataway, 
NJ). Images were scanned followed by densitometry analysis 
with Alphazmager 2200 software (Silk Scientific). The ratios 
of the specific antibodies/毬-actin were determined for the 
expression level of the proteins.
2.11. Statistical analysis
  The database was set up with the SPSS 15.0 software 
package (SPSS Inc, Chicago, IL) for analysis. Data were 
represented as mean暲SD. The means of multiple groups 
were compared with one-way ANOVA, after the equal 
check of variance, and the two-two comparisons among the 
means were performed using the LSD method. Statistical 
comparison was also performed with two-tailed t-test 
when appropriate. P<0.05 was considered as statistically 
significant.
3. Results
3.1. Effects of casticin on cytotoxicity of NSCLC cell lines
  To characterize the effect of casticin on cytotoxicity, three 
kinds of human NSCLC cell lines, including H460, A549, 
H157 cells and human embryo lung WI-38 cells were treated 
with various concentrations of casticin and cisplatin for 24 h,
and the cytotoxicity was assessed by MTT assay. Casticin 
and cisplatin were toxic to H460, A549, H157 and WI-38 
cells with IC50 values as shown in Table 1. The potency of 
casticin to NSCLC cells was stronger than that of cisplatin. 
The selective index of cytotoxicity to NSCLC cells of casticin 
was 37 (86.7/2.3), 27(86.7/3.2), 48(86.7/2.3) which was higher 
than that of cisplatin with a SI of 7.8(38.5/9.3), 2.3(38.5/16.4), 
1.7(38.5/22.6).
Table 1
IC50 values of casticin and cisplatin in H460, A549, H157 and WI-38 
cells.
Cell lines
IC50 (毺mol/L)*
Casticin Cisplatin
H 460   2.3暲0.2   4.9暲0.5
A549   3.2暲0.4 16.4暲1.4
H157   1.8暲0.1 22.6暲2.3
WI-38 86.7暲5.6 38.5暲3.3
*Means and standard deviations are calculated from triplicates of 
three independent experiments.
3.2. Induction of apoptosis by casticin in human NSCLC cells
   To elucidate whether casticin inhibits cell growth through 
the induction of apoptosis in the NSCLC cells, we then 
examined the effects of casticin on apoptosis in three NSCLC 
cell lines (A549, H460, and H157) using different approaches. 
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Using flow cytometric analysis to detect increases in 
hypodiploid cell populations, casticin increased the 
percentage of the sub-G1 population in H460, A549 and H157 
cells (P < 0.05), respectively reaching 37.5%暲5.7%, 26.8%暲
4.8% and 42.2%暲6.1% after 24 h of treatment with casticin 
at 4 毺mol/L (Figure 2A). The sub-G1 population in H157 
cells by casticin was increased at 12 h and peaked at 24 h 
(Figure 2B). Histone/DNA fragments in H460, A549 and H157 
cells, as measured by the cell apoptosis ELISA detection 
kit, were increased in dose-dependent manner (P<0.05) 
after treatment with casticin (Figure 2C). Furthermore, 
DNA fragmentation analysis by agarose gel electrophoresis 
showed a typical ladder pattern of internucleosomal DNA 
fragments in A549, H460, and H157 cells treated with 4 毺mol/L
casticin for 24 h (Figure 2D). These results suggest that 
casticin inhibited human NSCLC cells growth through a 
mechanism involving the induction of apoptosis.
H460       A549        H157
80
60
40
20
0
Su
b-
G
1 p
op
ul
at
io
n 
(%
)
2  4   8    2  4   8   2   4   8
Casticin (毺mol/L)
0.1
% 
DM
SO
2.36%
0 h
2.96%
16.9% 42.3%12 h 12 h
6 h
132
99
66
33
0
C
ou
nt
C
ou
nt
52
39
26
13
0
0    200    400  600    800   1 000 0    200    400   600   800   1 000
F1 F1
0    200    400   600   800   1 000
F1
0    200    400   600   800   1 000
F1
H460        A549      H157
8
6
4
2
0
2   4    8   2   4   8    2   4   80.1%
DMSO Casticin (毺mol/L)
M  1   2  3   4   5  6   7
2 000 bp
1 500 bp
750 bp
500 bp
100 bp
A B
C D
Figure 2. Apoptotic effects of casticin detected by flow cytometric 
analysis (A and B), cell apoptosis ELISA detection kit (C), and DNA 
agarose gel electrophoresis (D). 
*P<0.05, ** P<0.01 vs. treatment with DMSO; #P<0.05 vs. treatment 
with 2.0 毺mol/L casticin. M, DNA marker (DL2000); 1, H460 cells were 
treated with 0.1% DMSO for 24 h; 2, A549 cells were treated with 0.1% 
DMSO for 24 h; 3, H157 cells were treated with 0.1% DMSO for 24 h; 
4, H460 cells were treated with 4.0 毺mol/L casticin for 24 h; 5, A549 
cells were treated with 4.0 毺mol/L casticin for 24 h; 6, H157 cells were 
treated with 4.0 毺mol/L casticin for 24 h; 7, H157 cells were treated 
with 20.0 毺mol/L zVAD-fmk for 1 h, followed by in combination with 
4.0 毺mol/L casticin for 24 h.
3.3. Effects of casticin on caspases activities of human 
NSCLC cells
  To determine the effectors active in casticin-induced 
apoptotic pathways, we next examined whether caspases 
were actually activated during casticin induced cell death 
of human NSCLC cells. Figure 3A, B and C shows that 
treatment of human NSCLC cells with casticin for 24 h 
increased the levels of active caspase-3, -8. and -9 (P<0.05) 
in a concentration-dependent manner in H460, A549 and 
H157 cells respectively.
  We further examined the role of caspases activated during 
apoptosis induced by casticin treatment using the pan-
caspase inhibitor zVAD-fmk, the caspase-3 inhibitor 
zDEVD-fmk, the caspase-8 inhibitor zIETD-fmk and the 
caspase-9 inhibitor zLEHD-fmk. Figure 3D shows that 
zVAD-fmk and zDEVD-fmk completely abrogated apoptosis 
induced by casticin and zIETD-fmk and zLEHD-fmk 
attenuated casticin-induced apoptosis in H460, A549 and 
H157 cells respectively. These data indicate that casticin 
induced apoptosis was essentially dependent on activation 
of caspase-3, -8 and -9. 
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Figure 3. Effects of casticin on the caspase activities of lung cancer 
cells. 
A: H460, B: A549, C: H157 cell lines. D, Cells were pretreated with 
specific caspase inhibitor (20.0 毺mol/L zVAD-fmk or zDEVD-fmk 
or zIETD-fmk or zLEHD-fmk) for 1 h, followed by co-treatment with 
4.0 毺mol/L casticin for 24 h. *P<0.05, ** P<0.01 vs. treatment with 
DMSO; #P<0.05 vs. treatment with 2.0 毺mol/L casticin.  
3.4. Effects of casticin on apoptosis induction for 
mitochondrial signaling of human NSCLC cells
  Because casticin induced caspase-9 activation (Figure 3A), 
we wondered whether it affected casticin-induced apoptosis 
associated with mitochondrial signaling as well. Therefore, 
we next examined the effects of casticin on several important 
events for apoptosis such as mitochondrial membrane 
depolarization, cytochrome c release, and expression of some 
vital protein substrates in this pathway in H157 cells. The 
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results in Figure 4 indicate that: (i) treatment with casticin 
clearly elicited mitochondrial transmembrane potential (吟
毞m) dissipation, as indicated by the decrease in rhodamine 
123-derived fluorescence in flow cytometry assays (Figure 
4A). (ii) Casticin triggered a rapid release of cytochrome 
c from mitochondria to cytoplasm, as determined by 
immunoblot using cytosolic extracts (Figure 4B). The release 
of cytochrome c occurred as early as 3 h after treatment, 
and, therefore, preceded the increase of sub-G1 populations, 
which occurred after a 12-h treatment in NSCLC cells 
(Figure 2B). (iii) Treatment with castisin did not affect total 
Bcl-2 expression but caused a decrease in Bcl-XL and 
XIAP expression and a increase in Bax expression (Figure 
4C). The treatment also caused a decrease in the amount of 
Bid proform (21 kDa), which represents an indirect evidence 
of protein truncation/activation (Figure 4D). These data 
demonstrate casticin induced apoptosis was involved in the 
mitochondrial executioner pathway in H157 cells.
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Figure 4. Effects of casticin on mitochondrial membrane potential 
in lung cancer cells (A), and cytochrome c release (B), Bcl-2/Bcl-XL/
XIAP (C) and Bid protein expression in H157 cells. 
*P<0.05, ** P<0.01 vs. treatment with DMSO; #P<0.05 vs. treatment 
with 2.0 毺mol/L casticin.  
3.5. Effects of casticin on DR5 expression of human NSCLC 
cells
  Because casticin induced caspase-8 activation (Figure 3A) 
and a decrease in the amount of Bid proform (Figure 4D), 
the observation led us to investigate the effect of casticin 
on expression of DR4 and DR5 proteins. In H157 cell line, 
casticin increased expression of DR5 at protein levels but 
did not affect the expression of DR4 (Figure 5A).  
  To further definite the role of DR5 upregulation in 
casticin-induced apoptotic cell death, we examined the 
effects of DR5/Fc chimera protein, a blocking antibody, on 
induction of apoptosis by casticin. Figure 5B shows that 
the pretreatment with DR5/Fc chimera protein effectively 
attenuated casticin-induced apoptosis in H157 cells. These 
data suggest casticin induced apoptosis was associated with 
DR5 upregulation in human lung cancer H157 cell line.
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Figure 5. Casticin increases DR5 protein levels in lung cancer cells. 
A, H157 cells were treated with 4.0 毺mol/L casticin for the indicated 
time, and Western blotting of DR5, DR4 and 毬-actin as a loading 
control was done. B, Effect of DR5-specific blocking chimera antibody 
on casticin-induced apoptosis.
*P<0.05, ***P<0.01 vs. treatment with DMSO; ##P<0.01, ###P<0.05 
vs. treatment with 4.0 毺mol/L casticin alone.  
4. Discussion
   Casticin, a polymethoxyflavone from Fructus viticis, widely 
used as an anti-inflammatory agent in Chinese traditional 
medicine[5], was reported to have anticancer activities[6,7]. In 
the present study, we investigated the effects of casticin on 
the cell growth and apoptosis using a panel of human NSCLC 
cell lines. We have demonstrated that casticin was a potent 
agent in decreasing the growth of human NSCLC cells. 
Therefore, casticin may be a promising candidate for use as 
a therapeutic agent for cancer treatment. Casticin inhibited 
the growth of human NSCLC cells through induction of 
apoptosis. Therefore, our results warrant additional studies 
on the therapeutic activity of casticin in vivo[6,7,16-20]. 
  Caspases play important roles in apoptosis triggered by 
various proapoptotic signals[21,22]. In general, activation of 
the caspase cascade requires both initiator caspases such as 
caspase-8, and -9 and effector caspases such as caspase-3. 
The effector caspases cleave several vital substrates 
leading to apoptosis[21,22]. It has been well documented 
recently that the dissipation of 吟毞m, cytochrome c 
release from mitochondria and its activation of caspase-9 
through binding to the protein Apaf-1 is thought to mediate 
apoptosis triggered by signals such as chemotherapeutic
agents[21-24].In this study, casticin triggered (吟毞m)
dissipation, a rapid release of cytochrome c from 
mitochondria to cytosol, activated caspase-9 and caspase-3, 
followed by DNA fragment. Moreover, the pan-caspase 
inhibitor zVAD-FMK and the caspase-3 inhibitor zDEVD-
FMK blocked and the caspase-9 inhibitor zLEHD-fmk 
suppressed casticin-induced apoptosis. Therefore, we 
conclude that casticin induces mitochondrial dysfunction 
and a cytochrome c-mediated, caspase-dependent 
apoptosis in human NSCLC cells.
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  Bcl-2, Bcl-XL, and Bax have been implicated as major 
players in the control of apoptosis[21-23]. Bcl-2 and Bcl- 
XL promote cell survival, whereas Bax promotes cell 
death[25,26]. More recently, these proteins have been found to 
regulate apoptosis by controlling cytochrome c release from 
mitochondria and activation of caspase-9[25,27]. Casticin did 
not alter the expression levels of Bcl-2, but it did down-
regulate Bcl-XL and upregulate Bax. Whether the increase 
ratio of the Bax/Bcl-XL plays a role in casticin-induced 
apoptosis of human NSCLC cells remains to be elucidated. 
It has been reported that the release of cytochrome c 
from mitochondria to the cytosol, which is required for 
apoptosome assembly and subsequent activation of caspase-
9/-3, and XIAP down-regulation, which relieves caspases 
from the inhibitory action exerted by that protein[28]. 
Moreover, IAPs are degraded by the ubiquitin-proteasome 
system[29], and earlier studies reported an increase in 
ubiquitin-conjugated proteins in flavonoid-treated cells[30]. 
Therefore, XIAP down-regulation probably reflects an 
increase in protein degradation. Our findings demonstrate 
that casticin-induced apoptosis of human NSCLC cells is 
involved in mitochondrial executioner pathway.
  Of note, in addition to the mitochondrial pathway, casticin 
succeeded in activating the caspase-8/Bid pathway. 
The possibility that caspase-8 activation by casticin 
is a death receptor-mediated event, or alternatively 
represents a secondary event derived from mitochondrial 
activation[26,27]. Our findings demonstrated that casticin 
increased expression of DR5 at protein levels but did not 
affect the expression of DR4 in H157 cell line. Apoptosis by 
casticin is totally abrogated by the pan-caspase inhibitor 
z-VAD-fmk but only partially reduced by the caspase-8-
specific inhibitor z-IETD-fmk and DR5/Fc chimera protein, 
a blocking antibody, suggesting that the caspase-8/Bid 
activation functions as an amplification loop for the final 
apoptotic result.
  The cancer suppressor p53 is another important factor that 
affects the cell response to drug effects on growth inhibition 
and apoptosis induction[31,32]. The majority of evidence 
supports the notion that cells with wild-type p53 exhibit 
increased sensitivity to radiation or chemotherapeutic 
agents, whereas cells lacking wild-type p53 expression 
still undergo apoptosis but need a relatively high dose of 
radiation or chemotherapeutic drugs[31,32]. The investigation 
by Ha佾dara et al[18] demonstrated that casticin induced the 
apoptotic cell death in p53 mutant or null breast cancer cell 
lines. In the present study, we found that casticin inhibited 
cell growth and induced apoptosis regardless of p53 status 
in human lung cancer cells. Therefore, we conclude that 
casticin-induced apoptosis in human lung cancer cells is 
p53-independent.
  In conclusion,  we have demonstrated that  the 
polymethoxyflavone from Fructus viticis, casticin is a potent 
apoptosis-inducing agent in human NSCLC cells, which acts 
through both pathways involving mitochondria and death 
receptor, and subsequent activation of caspases. Moreover, 
casticin induces apoptosis independent of p53 status. Based 
on these findings, we suggest that casticin may be a good 
candidate for additional evaluation as a cancer therapeutic 
agent for human lung cancer as well as other types of cancer.
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